Eagle's Eye View: Your Weekly CV Update From ACC.org Carvedilol To Treat HFimpEF; Modifiable Lifestyle Factors & Cardiac Conduction Disease; Amiloride vs. Spironolactone for Resistant Hypertension
6 snips
May 28, 2025 This week, the discussion focuses on the CATHEDRAL-HF Trial, highlighting carvedilol's role in treating heart failure with improved ejection fraction. The impact of modifiable lifestyle factors on reducing cardiac conduction disease risk is also examined. Lastly, there's a comparison of amiloride and spironolactone for resistant hypertension, showcasing that both drugs lower systolic pressure, but amiloride may be better tolerated by certain patients. Tune in for insights on enhancing cardiac health!
AI Snips
Chapters
Transcript
Episode notes
Carvedilol Monotherapy in HFimpEF
- Maximizing carvedilol dosage and withdrawing other heart failure drugs can maintain improved ejection fraction.
- This suggests beta blocker optimization might be key in managing heart failure with improved EF.
Lifestyle's Impact on Cardiac Conduction
- Modifiable lifestyle factors strongly influence the development of cardiac conduction disease.
- Smoking, heavy alcohol use, sedentary behavior, and abnormal sleep increase risk of conduction abnormalities.
Amiloride Alternative for Hypertension
- Consider amiloride as an alternative for resistant hypertension when spironolactone is not tolerated.
- Both drugs similarly reduce blood pressure with low rates of side effects like hyperkalemia or gynecomastia.